Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

The researchers, led by Akrit Sodhi, MD, PhD, reported in the Proceedings of the National Academy of Sciences new findings ...

Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think ...

Current treatments sometimes fail to help people with “wet” age-related macular degeneration-- and researchers now think they ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

called anti-VEGF (vascular endothelial growth factor) drugs. Unfortunately, these anti-VEGF drugs might actually hamper vision improvements by triggering the over-expression of a second blood ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia ...

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...